^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BAY 1125976

    i
    Other names: BAY 1125976
    Company:
    Bayer
    Drug class:
    AKT1 inhibitor, AKT2 inhibitor
    Related drugs:
    5years
    Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer-Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy. (PubMed, Cancers (Basel))
    BAY 1125976 was well tolerated and inhibited AKT1/2 signaling but did not lead to radiologic or clinical tumor responses. Thus, the refinement of a selection of biomarkers for AKT inhibitors is needed to improve their monotherapy activity.
    Clinical • P1 data • Journal
    |
    AKT1 (V-akt murine thymoma viral oncogene homolog 1)
    |
    BAY 1125976